Merck Discontinues the P-III (KEYLYNK-008) Study of Keytruda (pembrolizumab) + Lynparza (olaparib) for Metastatic Squamous NSCLC
Shots:
- Merck has halted its P-III (KEYLYNK-008) study, as suggested by an independent DMC which revealed that, at interim analysis (IA3), Keytruda + CT followed by Keytruda + Lynparza, did not show improved OS vs Keytruda + CT followed by PBO
- Furthermore, the PFS did not attain statistical significance at the 2nd interim analysis, although there was a numerical improvement vs the control arm. The safety profile was consistent without any new safety signals identified. Data is anticipated at an upcoming scientific congress
- The randomized, triple-blind P-III (KEYLYNK-008) study investigated Keytruda + CT (carboplatin + paclitaxel/nab-paclitaxel) followed by Keytruda + maintenance Lynparza for the 1L treatment of metastatic squamous NSCLC
Ref: Merck | Image: Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
